The primary purpose of this study is to quantify the change in expression of biomarkers on the ocular surface of Sjogren's Syndrome participants after treatment with Maxidex.

Inclusion Criteria of Sjorgren's Population:

Inclusion Criteria:

• 17 years or older
• LogMar visual acuity of 0.6 or better
• Ocular inflammation associated with Sjogren's Syndrome

Exclusion Criteria:

• Has had an adverse reaction to either topical of systemic steroids in the past
• Has diabetes (type 1 or 2)
• Has glaucoma or evidence of ocular hypertension in either eye or treatment of either within six months of Visit 1
• Has worn contact lenses within one week prior to Visit 1
• Has received ocular prescription therapy in the last 30 days
• Has active ocular infections or inflammation not associated with Sjogren's Syndrome.
• Has any finding in the vitreous, macula, retina or choroid that show signs of inflammation and/or any structural change that in the opinion of the investigator is considered abnormal or unstable for that participant

Adverse reporting began once the patient enrolled into the study and went on for the duration of the study (6 weeks).